Pfizer and biontech announce phase 3 trial data showing high efficacy of a booster dose of their covid-19 vaccine

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced topline results from a phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-Μg booster dose of the pfizer-biontech covid-19 vaccine in more than 10,000 individuals 16 years of age and older. in the trial, a booster dose administered to individuals who previously received the pfizer-biontech primary two-dose series restored vaccine protection against covid
BNTX Ratings Summary
BNTX Quant Ranking